FindTrial
Sign In

Dose Ranging and Dose Frequency of LIPO-102

A Dose-Ranging and Dose Frequency Study Evaluating the Safety and Efficacy of LIPO-102 for the Reduction of Abdominal Subcutaneous Adipose Tissue

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00918814
Enrollment
54
Registered
2009-06-11
Start date
2009-06-30
Completion date
2010-02-28
Last updated
2015-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subcutaneous Adipose Tissue Reduction

Brief summary

Dose Ranging and Dose Frequency of LIPO-102

Interventions

DRUGLIPO-102

Subcutaneous Injection

DRUGPlacebo

Placebo

Sponsors

Neothetics, Inc
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or non pregnant female * Good general health * Sufficient abdominal fat for injections * Signed informed consent

Exclusion criteria

* Known hypersensitivity to study drugs * Treatment with an investigational agent within 30 days of first dose

Design outcomes

Primary

MeasureTime frame
Safety: physical examinations, laboratory tests, AE assessment4 weeks treatment and 4 weeks follow up

Secondary

MeasureTime frame
Efficacy: change in subcutaneous abdominal adipose tissue thickness4 weeks treatment and 4 weeks follow up

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026